Back to top

oncology-screening: Archive

Zacks Equity Research

Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study

Bristol Myers' (BMY) late-stage label-expanding study evaluating the Opdivo/Yervoy combination fails to meet the primary endpoint of progression-free survival in unresectable stage III NSCLC.

AZNPositive Net Change BMYNegative Net Change MRKNegative Net Change LGNDNegative Net Change

Zacks Equity Research

Guardant (GH) Gears Up for Q1 Earnings: Here's What to Expect

Investors' focus will likely be on revenues generated by Guardant Health (GH) from its precision oncology testing business.

ANIPNegative Net Change ANABNegative Net Change ARGXNegative Net Change GHPositive Net Change

Zacks Equity Research

Recursion (RXRX) to Report Q1 Earnings: What's in the Cards?

Recursion (RXRX) is expected to provide updates on its oncology and rare disease clinical-stage pipeline in its first-quarter earnings release, given the absence of a marketed product.

CPRXNegative Net Change ADVMNegative Net Change ARGXNegative Net Change RXRXNegative Net Change

Zacks Equity Research

GE Healthcare's (GEHC) Revolution RT to Aid Cancer Treatment

GE Healthcare (GEHC) unveils Revolution RT, along with other upgrades, from its portfolio during the ESTRO 2024 Congress.

BSXPositive Net Change ECLNegative Net Change ALGNNegative Net Change GEHCNegative Net Change

Zacks Equity Research

Fusion (FUSN) to Report Q1 Earnings: Here's What to Expect

Fusion (FUSN) is expected to provide updates regarding the developmental program of its lead candidate, FPI-2265, for prostate cancer in the first-quarter earnings release.

AZNPositive Net Change MRKNegative Net Change SRPTPositive Net Change FUSNNegative Net Change

Zacks Equity Research

ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study

ALX Oncology (ALXO) announces positive results from an early to mid-stage study of an investigational combination regimen to treat indolent and aggressive R/R B-NHL.

RHHBYPositive Net Change BMYNegative Net Change ALXONegative Net Change NRIXNegative Net Change

Zacks Equity Research

Nurix (NRIX) Up on Upbeat Initial Data From Phase I Cancer Study

Nurix (NRIX) rises on initial findings of clinical responses in the brain for its investigational targeted protein degrader, NX-5948, which is currently under development to treat B cell malignancies.

SNYNegative Net Change AZNPositive Net Change RHHBYPositive Net Change NRIXNegative Net Change

Zacks Equity Research

Agilent (A) is Set for Analytica 2024 With Advanced Products

Agilent (A) plans to showcase its new products for analytical laboratories at Analytica 2024, boosting its overall product portfolio.

APositive Net Change INCYNegative Net Change AMENegative Net Change AMATNegative Net Change

Zacks Equity Research

Agilent (A) to Bolster DCG Segment With Upcoming Solutions

Agilent (A) plans to introduce new solutions for cancer research and diagnosis, boosting its DCG segment.

APositive Net Change AMENegative Net Change AMATNegative Net Change BLPositive Net Change